ArticleEuropean radiology2026
Personalized dosimetry enhances hepatocellular carcinoma response in Yttrium-90 resin microsphere radioembolization.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify a tumor-mean absorbed dose (Dmean) that can predict response to Yttrium-90 resin-microsphere transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC) and evaluate its efficacy and safety. MATERIALS AND
methodsPatients with HCC eligible for TARE in two centers between January 2020 and May 2024 were retrospectively analyzed. Clinical, radiological, and procedural data were collected. Objective response rate (ORR) on lesion, complete response (CR), overall response, time-to-local progression (TLP), and time-to-progression (TTP) were evaluated on contrast-enhanced CT at 3 and 6 months according to mRECIST. The optimal Dmean of ORR on the target lesion and of CR was identified with ROC analysis at 3-months. Fischer's test compared ORR, Kaplan-Meier survival outcomes, and Cox regression was used for uni-and multivariable analyses.
resultsSeventy-six lesions in 64 patients (mean age 71.3 ± 9.6; 54 men) were evaluated. Median follow-up was 15.0 months (IQR 8.0-24.3). Mean tumor diameter was 55.2 (± 31.8) mm. CR on target lesion at 3-months was achieved in 42 lesions. Mean TLP and OS were 27.6 ± 2.5 and 36.2 ± 2.9 months, respectively. The calculated Dmean for ORR was 296.74 Gy (specificity 100, PPV 100%). Patients treated with equal or lower doses had a significantly shorter TLP (log-rank p = 0.001). Dmean > 296.74 Gy did not increase the risk of complications. A Dmean > 435.11 Gy predicts CR.
conclusionA Dmean threshold of 296.74 Gy provides significant therapeutic efficacy without compromising patient safety. All HCC lesions treated with > 435.11 Gy achieved CR. KEY POINTS: Question In patients with HCC treated with 90Y-resin microsphere TARE, can an optimized personalized dose improve efficacy without compromising safety? Findings The calculated mean dose (Dmean), even though above guideline indications, did not yield serious adverse events whilst enhancing response to treatment. Clinical relevance HCC recurrence is associated with poor patient outcomes. Personalized dosimetry is best practice for tailoring radioactive doses, and the cut-off dose calculated in this cohort identifies that with the best response and yields additional data on resin microsphere doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.